NCT07655804 Subcutaneous Calcitonin in Acute Herpes Zoster
| NCT ID | NCT07655804 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Tanta University |
| Condition | Calcitonin |
| Study Type | INTERVENTIONAL |
| Enrollment | 168 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 168 participants in total. It began in 2026-07-01 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.
Eligibility Criteria
Inclusion Criteria: * patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \< 7 days) and moderate to severe pain. Exclusion Criteria: * Coagulation abnormalities * Pre-existing other pain syndrome or psychological disorders. * Severe hepatic, cardiovascular, or renal disorders. * Allergy to calcitonin.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07655804 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Calcitonin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07655804 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 168 participants.
Is NCT07655804 currently recruiting?
Yes, NCT07655804 is actively recruiting participants. Contact the research team at marmoramero999@gmail.com for enrollment information.
Where is the NCT07655804 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07655804 clinical trial?
NCT07655804 is sponsored by Tanta University. The trial plans to enroll 168 participants.